IN8BIO, Inc. (INAB): R&D Expense
$10.21M
Year ended 2025-12-31
$9.86M
Trailing 12 months to 2026-06-30
-10.1%
3-year compound annual growth
+13.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.21M | -39.8% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $16.96M | +0.8% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $16.83M | +19.7% | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | $14.06M | +91.4% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $7.35M | +36.6% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $5.38M | n/a | 2022-03-17, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| IN8BIO, Inc. (INAB) | 2025-12-31 | $10.21M | -39.8% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $20.66M | -37.7% |
| Jasper Therapeutics, Inc. (JSPR) | 2025-12-31 | $63.10M | +13.0% |
| CEL SCI Corp (CVM) | 2025-09-30 | $15.89M | -12.5% |
| Windtree Therapeutics Inc (WINT) | 2024-12-31 | $16.28M | +95.1% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $9.08M | +33.1% |
| Pluri Inc. (PLUR) | 2026-06-30 | $15.09M | +17.4% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $39.75M | +23.7% |
| PharmaCyte Biotech, Inc. (PMCB) | 2026-04-30 | $391.3K | -10.7% |
Compare INAB, INMB, JSPR, CVM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗